Skip to main content
LLY
NYSE Life Sciences

FDA Approves Every Eight-Week Dosing for Eli Lilly's EBGLYSS in Atopic Dermatitis

Tom Rudovsky · Reported by PR Newswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1,143
Mkt Cap
$1.078T
52W Low
$623.78
52W High
$1,182.73
52W Position info
83% above low
Off High info
3.4% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

LLY sits 83% above its 52-week low of $623.78.

Summary

The FDA has approved a new, less frequent maintenance dosing regimen for Eli Lilly's EBGLYSS (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis, allowing for one dose every eight weeks. This approval provides patients with the option of as few as six injections per year, significantly improving convenience compared to the previously approved once-monthly schedule. This positive regulatory update enhances EBGLYSS's competitive profile in the dermatology market, potentially boosting patient adherence and market penetration for the drug. This follows a period of significant positive news for Eli Lilly, including the FDA approval of its weight-loss drug Foundayo and strong financial performance.

At the time of this announcement, LLY was trading at $1,143.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 12, 2026, 8:30 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $1,452.70
Real-time Price: $1,439.99 info
Change: -$12.70 (-0.87%) info
Market Cap: $1.358T info
LLY
Nov 12, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $1,447.85
Real-time Price: $1,439.99 info
Change: -$7.86 (-0.54%) info
Market Cap: $1.358T info
LLY
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1,411.12
Real-time Price: $1,439.99 info
Change: +$28.87 (+2%) info
Market Cap: $1.358T info
LLY
Nov 09, 2026, 10:23 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,394.15
Real-time Price: $1,439.99 info
Change: +$45.84 (+3%) info
Market Cap: $1.358T info
LLY
Nov 06, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,346.00
Real-time Price: $1,439.99 info
Change: +$93.99 (+7%) info
Market Cap: $1.358T info